严重财务造假，或强制退市！对中介同步核查！

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued an administrative penalty notice to Changjiang Pharmaceutical Holdings Co., Ltd. (*ST Changyao) for suspected false financial reporting, indicating a significant regulatory crackdown on financial misconduct in the market [1][5]. Group 1: Regulatory Actions - The CSRC has initiated an administrative penalty against *ST Changyao for suspected false records in periodic reports and financial data [1]. - The Shenzhen Stock Exchange will commence delisting procedures due to *ST Changyao's involvement in major illegal activities that could lead to forced delisting [2]. - The CSRC plans to investigate the practices of intermediary institutions involved with *ST Changyao [1][16]. Group 2: Financial Misconduct - *ST Changyao has been found to have inflated revenue and profits for three consecutive years (2021-2023), violating securities laws [5]. - The company reported inflated revenues of 215.32 million yuan, 283.74 million yuan, and 233.63 million yuan for the years 2021, 2022, and 2023, respectively, representing 9.12%, 17.57%, and 19.51% of the disclosed revenue [5]. - The inflated profit totals were 56.40 million yuan, 63.38 million yuan, and 43.71 million yuan for the same years, accounting for 35.62%, 88.23%, and 6.42% of the disclosed profit [5]. Group 3: Company Background - *ST Changyao, originally known as Kangyue Technology, was established in 2001 and listed on the Shenzhen Stock Exchange in August 2014 [6]. - The company entered the pharmaceutical industry in 2020 after acquiring a majority stake in Hubei Changjiang Star Pharmaceutical Co., Ltd. [6]. - The former actual controller, Luo Ming, continued to manage the company and was involved in the financial misconduct [6]. Group 4: Financial Health and Risks - As of the end of 2024, *ST Changyao reported a negative net asset of -432.84 million yuan and a significant decline in revenue from 1.615 billion yuan in 2022 to 112 million yuan in 2024 [10][12]. - The company faces multiple risks, including potential bankruptcy due to failure to meet restructuring conditions and significant overdue debts [12][14]. - The company has been under investigation since November 7, and the regulatory environment has tightened, leading to a record number of companies facing forced delisting this year [1][18].